Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19350804 | LIGAND DISCOVERY AND GENE DELIVERY VIA RETROVIRAL SURFACE DISPLAY | October 2025 | January 2026 | Allow | 3 | 1 | 0 | No | No |
| 19350928 | LIGAND DISCOVERY AND GENE DELIVERY VIA RETROVIRAL SURFACE DISPLAY | October 2025 | January 2026 | Allow | 3 | 1 | 0 | No | No |
| 19183257 | SYNTHETIC MODIFIED VACCINIA ANKARA (SMVA) BASED CORONAVIRUS VACCINES | April 2025 | November 2025 | Allow | 7 | 1 | 0 | Yes | No |
| 19014949 | LIGAND DISCOVERY AND GENE DELIVERY VIA RETROVIRAL SURFACE DISPLAY | January 2025 | July 2025 | Allow | 6 | 1 | 0 | No | No |
| 18742986 | METHODS AND PRODUCTS FOR GENETIC ENGINEERING | June 2024 | March 2025 | Allow | 9 | 1 | 0 | Yes | No |
| 17270341 | BINDING PROTEIN OF NS1 PROTEIN | April 2024 | February 2025 | Allow | 47 | 2 | 0 | No | No |
| 18440735 | IDENTIFYING PATIENT POPULATIONS VULNERABLE TO VIRAL INFECTION AND METHODS OF INDUCING HETEROLOGOUS IMMUNITY IN SAME | February 2024 | September 2025 | Abandon | 19 | 1 | 0 | No | No |
| 18440344 | ANTIBODIES AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF EPSTEIN BARR VIRUS INFECTION | February 2024 | May 2025 | Allow | 15 | 1 | 1 | No | No |
| 18435026 | MODIFIED CYTOMEGALOVIRUS PROTEINS AND STABILIZED COMPLEXES | February 2024 | April 2025 | Allow | 14 | 1 | 1 | Yes | No |
| 18416835 | VARICELLA ZOSTER VIRUS (VZV) VACCINE | January 2024 | September 2025 | Allow | 20 | 1 | 0 | Yes | No |
| 18515358 | GENETICALLY MODIFIED ANTI-THIRD PARTY CENTRAL MEMORY T CELLS AND USE OF SAME IN IMMUNOTHERAPY | November 2023 | August 2025 | Allow | 21 | 2 | 0 | No | No |
| 18509781 | METHODS FOR ANALYSIS OF VIRAL CAPSID PROTEIN COMPOSITION | November 2023 | July 2025 | Allow | 20 | 2 | 0 | No | No |
| 18506578 | HUMAN CYTOMEGALOVIRUS GB POLYPEPTIDE | November 2023 | June 2025 | Allow | 19 | 1 | 0 | No | No |
| 18496076 | Recombinant Cytomegalovirus Vectors As Vaccines For Tuberculosis | October 2023 | June 2025 | Allow | 19 | 2 | 0 | No | No |
| 18488604 | METHODS AND COMPOSITIONS FOR ANTIBODY-EVADING VIRUS VECTORS | October 2023 | February 2025 | Abandon | 16 | 0 | 1 | No | No |
| 18481204 | HERPES SIMPLEX VIRUS VACCINE | October 2023 | March 2025 | Abandon | 17 | 1 | 0 | No | No |
| 18474014 | METHODS OF MAKING FUCOSYLATED AND AFUCOSYLATED FORMS OF A PROTEIN | September 2023 | April 2025 | Allow | 19 | 1 | 0 | No | No |
| 18458657 | LIGAND DISCOVERY AND GENE DELIVERY VIA RETROVIRAL SURFACE DISPLAY | August 2023 | September 2024 | Allow | 13 | 2 | 0 | Yes | No |
| 18452624 | MULTIVALENT RECOMBINANT AVIAN HERPES VIRUSES AND VACCINES FOR IMMUNIZING AVIAN SPECIES | August 2023 | June 2025 | Allow | 22 | 2 | 0 | No | No |
| 18232437 | VETO CELLS GENERATED FROM MEMORY T CELLS | August 2023 | April 2025 | Allow | 20 | 1 | 0 | No | No |
| 18365948 | NUCLEIC ACID VACCINES FOR VARICELLA ZOSTER VIRUS (VZV) | August 2023 | July 2025 | Abandon | 23 | 5 | 0 | Yes | No |
| 18358350 | EPSTEIN-BARR VIRUS ANTIGEN CONSTRUCTS | July 2023 | January 2025 | Allow | 18 | 1 | 1 | Yes | No |
| 18354849 | Use of Triplex CMV Vaccine in CAR T Cell Therapy | July 2023 | July 2025 | Allow | 24 | 2 | 0 | No | Yes |
| 18355265 | DEVELOPMENT OF DENGUE VIRUS VACCINE COMPONENTS | July 2023 | September 2024 | Allow | 14 | 1 | 0 | No | No |
| 18354574 | HERPES SIMPLEX VIRUS VACCINE | July 2023 | March 2025 | Abandon | 20 | 1 | 0 | No | No |
| 18351392 | COMPOSITIONS AND METHODS FOR INDUCING IMMUNE RESPONSES | July 2023 | April 2025 | Allow | 21 | 2 | 0 | No | No |
| 18345893 | CORONAVIRUS VACCINE COMPOSITIONS AND METHODS | June 2023 | September 2024 | Allow | 15 | 1 | 0 | Yes | No |
| 18342284 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF WOUNDS, DISORDERS, AND DISEASES OF THE SKIN | June 2023 | November 2025 | Allow | 29 | 2 | 0 | Yes | No |
| 18342666 | SCALABLE PURIFICATION METHOD FOR AAV9 | June 2023 | August 2025 | Allow | 25 | 2 | 0 | No | Yes |
| 18335810 | HBV VACCINES AND METHODS TREATING HBV | June 2023 | May 2025 | Allow | 23 | 2 | 1 | Yes | No |
| 18334279 | MVA VACCINE FOR DELIVERY OF A UL128 COMPLEX AND PREVENTING CMV INFECTION | June 2023 | July 2024 | Allow | 13 | 1 | 0 | No | No |
| 18333718 | SCALABLE PURIFICATION METHOD FOR AAV1 | June 2023 | July 2024 | Allow | 13 | 1 | 0 | No | No |
| 18200997 | ANTIGEN DELIVERY PLATFORMS | May 2023 | December 2024 | Abandon | 19 | 1 | 0 | No | No |
| 18318061 | VACCINES AGAINST ZIKA VIRUS | May 2023 | May 2025 | Allow | 24 | 2 | 0 | Yes | No |
| 18141055 | Identification and Attenuation of the Immunosuppressive Domains in Fusion Proteins of Enveloped RNA Viruses | April 2023 | January 2025 | Abandon | 20 | 1 | 0 | No | No |
| 18297207 | SELF-ASSEMBLING PROTEIN NANOPARTICLES ENCAPSULATING IMMUNOSTIMULATORY NUCLEID ACIDS | April 2023 | January 2025 | Abandon | 21 | 1 | 0 | No | No |
| 18130375 | METHODS AND PRODUCTS FOR GENETIC ENGINEERING | April 2023 | September 2024 | Allow | 18 | 1 | 0 | Yes | No |
| 18189512 | RESPIRATORY VIRUS NUCLEIC ACID VACCINES | March 2023 | December 2024 | Abandon | 21 | 1 | 0 | No | No |
| 18183066 | TETRAVALENT ANTI-PSGL-1 ANTIBODIES AND USES THEREOF | March 2023 | December 2024 | Abandon | 21 | 1 | 0 | No | No |
| 18182212 | MEANS AND METHODS FOR TREATING HERPESVIRUS INFECTION | March 2023 | May 2025 | Allow | 26 | 2 | 0 | No | No |
| 18176014 | NUCLEIC ACID VACCINES FOR VARICELLA ZOSTER VIRUS (VZV) | February 2023 | November 2024 | Abandon | 20 | 2 | 0 | No | No |
| 18023580 | VACCINE COMPOSITION FOR CHICKENPOX OR VARICELLA ZOSTER AND METHOD OF USING SAME | February 2023 | October 2025 | Allow | 32 | 0 | 0 | Yes | No |
| 18165770 | ONCOLYTIC VIRAL VECTORS AND USES THEREOF | February 2023 | October 2024 | Allow | 20 | 1 | 0 | Yes | No |
| 18004065 | POLYPEPTIDE FRAGMENTS, IMMUNOGENIC COMPOSITION AGAINST SARS-CoV-2, AND IMPLEMENTATIONS THEREOF | January 2023 | March 2026 | Abandon | 38 | 0 | 1 | No | No |
| 18012879 | KIT AND METHODS FOR CHARACTERIZING A VIRUS IN A SAMPLE | December 2022 | February 2026 | Abandon | 38 | 1 | 0 | No | No |
| 18012343 | COMPOSITIONS AND METHODS FOR INDUCING AN IMMUNE RESPONSE AGAINST CORONAVIRUS | December 2022 | March 2026 | Abandon | 39 | 1 | 0 | No | No |
| 18145136 | VARICELLA ZOSTER VIRUS VACCINE | December 2022 | December 2025 | Abandon | 36 | 3 | 0 | No | No |
| 18060386 | STABLE FORMULATIONS OF CYTOMEGALOVIRUS | November 2022 | March 2025 | Abandon | 27 | 3 | 0 | No | No |
| 18071109 | HSV-2-DELTA-gD VACCINES AND METHODS FOR THEIR PRODUCTION AND USE | November 2022 | July 2024 | Allow | 20 | 2 | 0 | No | No |
| 17925988 | VIRAL VACCINE VECTOR FOR IMMUNIZATION AGAINST A BETACORONAVIRUS | November 2022 | January 2026 | Abandon | 38 | 1 | 0 | No | No |
| 17998737 | RECOMBINANT VACCINE AGAINST COVID-19 BASED ON A PARAMYXOVIRUS VIRAL VECTOR | November 2022 | December 2025 | Allow | 37 | 1 | 0 | Yes | No |
| 17938823 | ZOONOTIC DISEASE RNA VACCINES | October 2022 | June 2025 | Abandon | 32 | 3 | 0 | No | No |
| 17950308 | MULTIPLEXED LATERAL FLOW ASSAY FOR DETECTION OF HPV ASSOCIATED CANCER | September 2022 | November 2025 | Allow | 38 | 1 | 0 | No | No |
| 17802001 | CORONAVIRUS VACCINES | August 2022 | December 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17816060 | DIAGNOSIS OF CONGENITAL CYTOMEGALOVIRUS INFECTION | July 2022 | August 2025 | Allow | 36 | 1 | 0 | No | No |
| 17812732 | RECOMBINANT HVT VECTORS EXPRESSING MULTIPLE ANTIGENS OF AVIAN PATHOGENS AND USES THEREOF | July 2022 | April 2025 | Allow | 33 | 4 | 0 | Yes | No |
| 17855571 | AAV VECTOR AND ASSAY FOR ANTI-AAV (ADENO-ASSOCIATED VIRUS) NEUTRALIZING ANTIBODIES | June 2022 | November 2025 | Abandon | 41 | 5 | 0 | No | No |
| 17852891 | EXOGENOUS GENE EXPRESSION IN RECOMBINANT ADENOVIRUS FOR MINIMAL IMPACT ON VIRAL KINETICS | June 2022 | December 2024 | Allow | 29 | 2 | 0 | Yes | No |
| 17846296 | EPSTEIN-BARR VIRUS NUCLEIC ACID CONSTRUCTS AND VACCINES MADE THEREFROM, AND METHODS OF USING SAME | June 2022 | October 2025 | Allow | 40 | 6 | 0 | No | No |
| 17840478 | HUMAN CYTOMEGALOVIRUS VACCINE | June 2022 | November 2024 | Abandon | 29 | 3 | 0 | No | No |
| 17779011 | METHOD FOR DETECTING CYTOMEGALOVIRUS (CMV) AND MEASURING AND QUANTIFYING PENTAMERIC COMPLEX USING AN INDIRECT SANDWICH ELISA | May 2022 | January 2026 | Abandon | 44 | 2 | 0 | No | No |
| 17773277 | ONCOLYTIC VIROTHERAPY WITH INDUCED ANTI-TUMOR IMMUNITY | April 2022 | December 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17771595 | NOVEL ANTIBODIES FOR DETECTING EPSTEIN BARR VIRUS-POSITIVE GASTRIC CANCER | April 2022 | December 2025 | Allow | 44 | 1 | 0 | Yes | No |
| 17714307 | MODIFIED VIRUS-LIKE PARTICLES OF CMV | April 2022 | December 2025 | Allow | 44 | 3 | 0 | Yes | No |
| 17638344 | HEPATITIS B VIRUS VACCINES | February 2022 | September 2025 | Allow | 43 | 1 | 0 | Yes | No |
| 17670052 | COMPOSITIONS AND METHODS FOR TREATMENT OF CYTOMEGALOVIRUS | February 2022 | June 2025 | Allow | 40 | 1 | 0 | No | No |
| 17631808 | COMBINATION DRUG FOR TREATING MALIGNANT TUMOR, PHARMACEUTICAL COMPOSITION FOR TREATING MALIGNANT TUMOR, AND PHARMACEUTICAL COMPOSITION FOR MALIGNANT TUMOR TREATMENT | January 2022 | October 2025 | Abandon | 45 | 1 | 0 | No | No |
| 17628351 | MODIFIED HUMAN CYTOMEGALOVIRUS PROTEINS | January 2022 | June 2025 | Allow | 41 | 1 | 0 | No | No |
| 17577681 | METHODS AND COMPOSITIONS FOR TREATING INFECTIONS | January 2022 | October 2024 | Allow | 33 | 1 | 0 | No | No |
| 17553561 | Method and Apparatus for Rapid Virus Screening and Detection using a Canine | December 2021 | September 2025 | Abandon | 45 | 1 | 0 | No | No |
| 17535121 | VACCINES AGAINST HEPATITIS B VIRUS | November 2021 | September 2025 | Abandon | 46 | 4 | 0 | No | Yes |
| 17595124 | MODIFIED S2 SUBUNIT OF THE CORONAVIRUS SPIKE PROTEIN | November 2021 | February 2026 | Allow | 51 | 3 | 0 | Yes | No |
| 17510969 | VACCINATION USING HERPESVIRUS GENOMES IN NUCLEIC ACID FORM | October 2021 | June 2025 | Allow | 44 | 1 | 0 | No | No |
| 17604072 | Adeno-Associated Virus Vector Formulations and Methods | October 2021 | November 2025 | Abandon | 49 | 1 | 0 | No | No |
| 17475001 | VACCINE FOR USE AGAINST CORONAVIRUS AND VARIANTS THEREOF | September 2021 | March 2025 | Allow | 42 | 3 | 0 | No | No |
| 17407716 | MODIFIED CAPSID PROTEINS FOR ENHANCED DELIVERY OF PARVOVIRUS VECTORS | August 2021 | February 2025 | Allow | 41 | 4 | 0 | No | Yes |
| 17431856 | MULTIVALENT KAPOSI SARCOMA-ASSOCIATED HERPESVIRUS-LIKE PARTICLES AND USES THEREOF | August 2021 | July 2024 | Allow | 35 | 1 | 0 | Yes | No |
| 17420529 | PASSIVE TRANSFER OF IMMUNITY USING RECOMBINANT HERPES SIMPLEX VIRUS 2 (HSV-2) VACCINE VECTORS | July 2021 | May 2025 | Abandon | 46 | 2 | 0 | No | No |
| 17322054 | BIOMATERIAL-BASED COVID-19 VACCINE | May 2021 | October 2025 | Abandon | 53 | 5 | 0 | No | No |
| 17300287 | REPLICATION-COMPETENT CONTROLLED ALPHA-HERPESVIRUS VECTORS AND USES THEREFORE | May 2021 | November 2024 | Allow | 42 | 4 | 0 | No | No |
| 17290384 | RESPIRATORY SYNCYTIAL VIRUS RECOMBINANT F PROTEIN AND VACCINE COMPOSITION CONTAINING SAME | April 2021 | April 2025 | Allow | 47 | 1 | 0 | No | No |
| 17287698 | CANINE DISTEMPER VACCINES AND METHODS OF TREATMENT USING THE SAME | April 2021 | April 2025 | Allow | 48 | 3 | 0 | No | No |
| 17231534 | VACCINES HAVING AN ANTIGEN AND INTERLEUKIN-21 AS AN ADJUVANT | April 2021 | July 2024 | Allow | 40 | 3 | 0 | Yes | No |
| 17280803 | RECOMBINANT VIRAL VECTOR, IMMUNE COMPOSITION CONTAINING SAME, AND USE THEREOF | March 2021 | September 2024 | Allow | 41 | 2 | 0 | No | No |
| 17279501 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN DISEASES | March 2021 | February 2026 | Allow | 59 | 3 | 0 | No | No |
| 17273977 | Storage Improved Poxvirus Compositions | March 2021 | July 2024 | Allow | 41 | 2 | 0 | No | No |
| 17272096 | NS1-BINDING PROTEIN | February 2021 | January 2025 | Allow | 47 | 2 | 0 | Yes | No |
| 17272158 | NS1-BINDING PROTEIN | February 2021 | April 2025 | Allow | 50 | 2 | 0 | No | No |
| 17271287 | Recombinant Replication Competent Viruses Comprising a Coding Region for Glycogen Synthase Kinase-3 (GSK3) and Methods of Killing Aberrant Cells | February 2021 | December 2024 | Allow | 46 | 2 | 0 | No | No |
| 17269409 | VACCINES AGAINST NIPAH VIRUS, AND METHODS OF USING SAME | February 2021 | March 2025 | Allow | 49 | 3 | 0 | No | No |
| 17266827 | A VIRUS NEUTRALIZATION ASSAY UTILIZING IMAGING CYTOMETRY | February 2021 | September 2025 | Allow | 55 | 3 | 0 | No | No |
| 17264377 | METHODS AND COMPOSITIONS FOR ALPHAVIRUS VACCINE | January 2021 | February 2025 | Abandon | 48 | 3 | 0 | Yes | No |
| 17255517 | INFLUENZA VIRUS HEMAGGLUTININ MUTANTS | December 2020 | May 2025 | Allow | 53 | 2 | 1 | Yes | No |
| 17095318 | MVA VECTORS FOR EXPRESSING MULTIPLE CYTOMEGALOVIRUS (CMV) ANTIGENS AND USE THEREOF | November 2020 | September 2025 | Allow | 58 | 5 | 0 | Yes | No |
| 17091756 | FORMULATIONS OF ANTIBODY MOLECULES TO INFLUENZA VIRUS | November 2020 | November 2024 | Allow | 48 | 4 | 0 | No | No |
| 16982039 | VACCINE COMPOSITIONS | September 2020 | May 2025 | Allow | 56 | 4 | 0 | No | No |
| 16888398 | IMMUNOTHERAPEUTIC COMPOSITIONS FOR TREATMENT OF GLIOBLASTOMA MULTIFORME | May 2020 | January 2025 | Abandon | 55 | 3 | 0 | No | Yes |
| 16765285 | EPSTEIN-BARR VIRUS VACCINES | May 2020 | May 2025 | Abandon | 60 | 7 | 0 | No | No |
| 16762286 | PHARMACEUTICAL COMPOSITIONS, METHODS FOR PREPARATION COMPRISING SIZING OF LIPID VESICLE PARTICLES, AND USES THEREOF | May 2020 | February 2025 | Abandon | 57 | 4 | 0 | No | No |
| 16741827 | ENGINEERED HERPES SIMPLEX VIRUS-1 (HSV-1) VECTORS AND USES THEREOF | January 2020 | September 2024 | Allow | 56 | 4 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner GILL, RACHEL B.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 12.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner GILL, RACHEL B works in Art Unit 1671 and has examined 85 patent applications in our dataset. With an allowance rate of 85.9%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 35 months.
Examiner GILL, RACHEL B's allowance rate of 85.9% places them in the 63% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by GILL, RACHEL B receive 2.47 office actions before reaching final disposition. This places the examiner in the 72% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by GILL, RACHEL B is 35 months. This places the examiner in the 38% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +21.5% benefit to allowance rate for applications examined by GILL, RACHEL B. This interview benefit is in the 66% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 22.3% of applications are subsequently allowed. This success rate is in the 28% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 51.2% of cases where such amendments are filed. This entry rate is in the 77% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 93% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 87% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 60.0% are granted (fully or in part). This grant rate is in the 64% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 3% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 3% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.